Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-treatment Long-term Follow-up Study of ADVM-043 Gene Therapy in Alpha-1 Antitrypsin Deficiency

NCT03804021 is registered in ClinicalTrials.gov with Adverum Biotechnologies, Inc. as lead sponsor.

NCT NCT03804021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03804021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-treatment Long-term Follow-up Study of ADVM-043 Gene Therapy in Alpha-1 Antitrypsin Deficiency
Lead sponsor
Adverum Biotechnologies, Inc.
Phase
Observational
Overall status
Completed
Start date
December 27, 2018
Completion date
December 6, 2021
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alpha-1 antitrypsin deficiency